EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptide 6a a fibrin ogen degradation products increases coronary blood flow






American Journal of Physiology 249(3 PART 2): H457-H462

Peptide 6a a fibrin ogen degradation products increases coronary blood flow

The coronary hemodynamic effects of intracoronary administration of a fibrin(ogen)-derived pentapeptide, Ala-Arg-Pro-Ala-Lys (peptide 6A), were evaluated in open-chest anesthetized dogs. With administration of peptide 6A (2.5-30 .mu.mol), coronary blood flow increased and coronary vascular resistance decreased promptly in a dose-related manner. Increase in coronary blood flow was independent of any change in indexes of myocardial O2 demand, indicating the peptide 6A exerts direct effects on coronary arterial tone. Systemic arterial and left ventricular end-diastolic pressures remained unchanged with smaller doses but decreased when higher doses of peptide 6A (.gtoreq. 20 .mu.mol) were administered. Plasma concentrations of 6-ketoprostaglandin F1.alpha., stable hydrolysis product of prostacyclin, increased in coronary sinus blood samples in conjunction with increase in coronary blood flow. Administration of indomethacin (5 mg/kg iv) inhibited peptide 6A-induced release of prostacyclin and significantly attenuated the effects of peptide 6A on coronary hemodynamics. Pretreatment of animals with H2-receptor blocker cimetidine (500 mg iv) or with H1- and H2-receptor blocker diphenhydramine (50 mg iv) had no significant effects on peptide 6A-induced increase in coronary blood flow. This study suggests that this fibrin(ogen)-derived peptide has potent vasodilator effects on the coronary vascular bed of the dog, and these effects are in part mediated by stimulation of prostacyclin release.


Accession: 006079609

PMID: 3839977



Related references

Mehta, J.; Wargovich, T.; Nichols, W.W.; Saldeen, K.; Wallin, R.; Saldeen, T., 1985: Peptide 6A, a fibrin(ogen) degradation product, increases coronary blood flow. The coronary hemodynamic effects of intracoronary administration of a fibrin(ogen)-derived pentapeptide, Ala-Arg-Pro-Ala-Lys (peptide 6A), were evaluated in open-chest anesthetized dogs. With administration of peptide 6A (2.5-30 mumol), coronary b...

Saldeen, K.; Nichols, W.; Lawson, D.; Andersson, R.; Saldeen, T.; Mehta, J., 1991: Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. To determine the effects of peptide 6A (a fibrinogen-degradation product) on femoral blood flow, anaestetized dogs were given saline or peptide 6A intravenously in random order. Bolus injection of peptide 6A (10, 20 or 50 .mu.moles) caused a short...

Nichols, W.W.; Mehta, J.; Wargovich, T.; Saldeen, K.; Wallin, R.; Saldeen, T., 1985: Fibrin(ogen)-derived peptide B beta 30-43 increases coronary blood flow in the anesthetized dog. The hemodynamic effects of intracoronary administration of a fibrin (ogen)-derived peptide B beta 30-43 (Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Ala) were evaluated in open-chest anesthetized dogs. Coronary blood flow (CBF) increased a...

McCaw, D.L.; Jergens, A.E.; Turrentine, M.A.; Johnson, G.S., 1986: Effect of internal hemorrhage on fibrin(ogen) degradation products in canine blood. To determine effects of internal hemorrhage on fibrin(ogen) degradation products, blood was pumped from catheters in the jugular veins of 7 anesthetized dogs into extravascular sites in the same dogs. Blood (25 ml/kg of body weight) was transporte...

Forconi, S.; Guerrini, M.; Cappelli, R.; Furesi, L.; Battistelli, S.; Sani, P.; Marotta, G.; Trabalzini, L., 1993: Effect of fibrin(ogen) degradation products on blood viscosity values during thrombolysis. This study concerns the effect of intravenous thrombolysis in patients suffering from Peripheral Obliterative Arterial Disease (POAD) at the stage of "Accelerated Limb Ischemia" (ALI). In a previous study on 17 patients, where Streptokin...

Bini, A.K.dryk, B., 1991: Use of monoclonal antibodies to fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. NATO ASI series Series A Life sciences19(219): 189-197

Kołodziejczyk, J.; Ponczek, Mł.B., 2013: The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Participation of fibrin, fibrinogen, and their degradation products in pathogenesis and progression of cancer may lead to complications of thromboembolic events. The tumor may be a source of fibrinogen. Fibrinogen inside the tumor is one of the fa...

Bini, A.; Fenoglio, J.J.; Mesa-Tejada, R.; Kudryk, B.; Kaplan, K.L., 1989: Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Samples of normal and atherosclerotic vessels obtained from vascular and cardiothoracic surgery were examined for the distribution of fibrinogen/fibrin I, fibrin II, and fibrin(ogen) degradation products (Fragment D/DD) by using recently character...

Xiong, W-Xin.; Shen, Y.; Dai, D-Peng.; Lu, L.; Zhang, Q.; Zhang, R-Yan.; Shen, W-Feng.; Tao, R., 2015: Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients. We investigated whether and to what extent the ratio between circulating fibrinogen (Fg) and its degradation products (FDP) reflects the severity of coronary artery disease (CAD) in type 2 diabetic patients. Plasma levels of Fg and FDP were determ...

Suzuki, S.; Graeff, H.; Hafter, R., 1979: Content of soluble fibrin monomeric complexes, factor XIII and fibrin(ogen) degradation products in neonatal asphyxia. Archives of Gynecology 228(1-4): 626-627